Jacqueline Iversen’s Visionary Approach with innovative Pain Management
Jacqueline Iversen is transforming the pharmaceutical industry with proactive, low-cost solutions for pain management and wellness
Jacqueline Iversen, co-founder of Sen-Jam Pharmaceutical, revolutionizes pain management with proactive, low-cost therapeutics, driven by personal experiences and a commitment to improving global health through innovative drug development.
Jacqueline’s journey into the world of pharmaceuticals began during her research fellowship at Memorial Sloan Kettering. It was here that she identified a critical gap in the industry: the need to shift from reactive to proactive pain management strategies. Her experience as a hospital pharmacist, combined with her deep understanding of patient challenges, inspired her to co-found Sen-Jam Pharmaceutical with her husband, Jim. Jim, a logistics and efficiency expert, brought a unique perspective to the company, helping to cultivate an innovative approach to drug development. Together, they focus on creating low-cost, repurposed therapeutics aimed at reducing healthcare costs and expanding access to underserved populations.
Jacqueline Iversen is a name that stands out in the realm of pain management and wellness innovation. As the Co-Founder and Chief Clinical Officer of Sen-Jam Pharmaceutical, she has been at the forefront of transforming the pharmaceutical industry. With a robust background in pharmacokinetics and pain management, Jacqueline has spent over two decades contributing to scientific research, authoring more than 20 published papers. Her dedication to improving patient outcomes and her advocacy for proactive healthcare solutions have established her as a visionary leader in clinical research.
Sen-Jam Pharmaceutical‘s mission is driven by Jacqueline’s personal experiences and determination to address inflammation, pain, and addiction. Witnessing the devastation caused by unethical pharmaceutical practices and the widespread opioid crisis fueled her resolve to find alternative solutions. Jacqueline believes that drug development has the power to change prescribing practices and drug policies. Her research focuses on treating pain with non-opioid agents that also mitigate the harmful effects of opioids. Along the way, she has discovered new treatments to reduce inflammation and safely modulate the immune system, which are closely linked to pain and addiction.
Developing low-cost therapeutics for underserved populations comes with its own set of challenges. The pharmaceutical industry is crowded with companies focusing on repurposed drugs, while larger investors often prioritize “designer drugs” with high risk-to-reward ratios. This investment model can prolong drug development timelines, both for companies and patients. However, Sen-Jam Pharmaceutical sees an opportunity to rapidly develop innovative products at a low cost by targeting unique mechanisms of action with already available, safe drugs. Their nimble approach leverages new technologies such as artificial intelligence, digital clinical trials, and collaborative partnerships to bring superior solutions to patients quickly.
Looking to the future, Sen-Jam Pharmaceutical aims to make a significant impact on global health by extending healthy aging through safe immune system modulation. The immune system, now being mapped and understood as a complex web of cells and mediators, plays a crucial role in lifelong health. Sen-Jam’s mission is to support the immune system by monitoring its role in health and disease and treating inflammation proactively, before tissue damage and disease take root. By targeting inflammation with broad-spectrum anti-inflammatories, Sen-Jam seeks to change the course of inflammation for more than half the world’s population, addressing various forms of inflammation, including acute, chronic, autoimmune, and low-grade chronic inflammation.
For aspiring pharmacists and entrepreneurs looking to make a difference in the pharmaceutical industry, Jacqueline offers valuable advice. She emphasizes the importance of creativity and perseverance, encouraging individuals to bring fresh perspectives to entrenched problems. Trusting one’s instincts and following data-driven decision-making are crucial in driving meaningful change. Jacqueline believes that the industry needs creative problem solvers who are willing to explore new possibilities and face adversity with conviction.
Sen-Jam Pharmaceutical’s recent partnership with KVK-Tech, a world-class manufacturing and controls organization, is a testament to their commitment to innovation. This collaboration accelerates their drug development activities, allowing them to produce high-quality products efficiently. Together, they are working on developing the first mast cell modulating injectable for hospital use, offering a much-needed tool for physicians to transform patient care.
In conclusion, Jacqueline Iversen’s work at Sen-Jam Pharmaceutical is paving the way for a new era in pain management and wellness. Her dedication to proactive healthcare solutions, combined with her innovative approach to drug development, is making a significant impact on global health. As she continues to challenge industry norms and advocate for patient-centered care, Jacqueline remains a true wellness innovator, inspiring others to follow in her footsteps.
